Literature DB >> 32186582

Endocrinological late effects of oncologic treatment on survivors of medulloblastoma.

Antonio David Hidalgo Santos1, María Del Carmen de Mingo Alemany1, Francisca Moreno Macián1, Sara León Cariñena1, Erika Collado Ballesteros2, Adela Cañete Nieto3.   

Abstract

INTRODUCTION: Radiation therapy, chemotherapy, and surgery used to treat brain tumors have effects on the hy pothalamic-pituitary-adrenal axis and can result in endocrine dysfunction in up to 96% of cases. PATIENTS AND
METHOD: Retrospective and descriptive study in patients diagnosed with medulloblasto ma who underwent treatment with chemo and radiotherapy in the last 20 years in a tertiary hospital. The variables analyzed were age, sex, weight, height, body mass index (BMI) at the end of follow-up, sexual maturity stage, serum levels of TSH and free T4, ACTH/cortisol and IGF-1, FSH, LH, estradiol, testosterone, lipid profile (total cholesterol), and growth hormone dynamic function test.
RESULTS: Total sample of 23 patients. Growth hormone deficiency is the most frequent sequelae (82%) fo llowed by thyroid dysfunction (44.8%), and disorders of puberty (24.1%). Only one case of diabetes insipidus and two cases of corticotropin deficiency were diagnosed.
CONCLUSIONS: Long-term follow- up of medulloblastoma survivors treated with chemo and radiotherapy reveals a very high prevalence of endocrine dysfunction, especially growth hormone deficiency and hypothyroidism. We believe that monitoring and long-term follow-up of these patients is necessary in order to ensure adequate therapeutic management of those treatable dysfunctions.

Entities:  

Year:  2019        PMID: 32186582     DOI: 10.32641/rchped.v90i6.994

Source DB:  PubMed          Journal:  Rev Chil Pediatr        ISSN: 0370-4106


  2 in total

1.  Characteristics of growth disturbances in patients with intracranial germinomas of different origins.

Authors:  Bo Li; Jiayi Wang; Jiongxian Yang; Yanong Li; Yanwei Liu; Shuai Liu; Xiaoguang Qiu
Journal:  Childs Nerv Syst       Date:  2021-05-24       Impact factor: 1.475

Review 2.  Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice.

Authors:  Margaret C S Boguszewski; Adriane A Cardoso-Demartini; Cesar Luiz Boguszewski; Wassim Chemaitilly; Claire E Higham; Gudmundur Johannsson; Kevin C J Yuen
Journal:  Pituitary       Date:  2021-07-25       Impact factor: 4.107

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.